MML Investors Services LLC Has $275,000 Stock Holdings in Bruker Co. (NASDAQ:BRKR)

MML Investors Services LLC lowered its holdings in shares of Bruker Co. (NASDAQ:BRKR – Get Rating) by 11.4% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,187 shares of the medical research company’s stock after selling 666 shares during the period. MML Investors Services LLC’s holdings in Bruker were worth $275,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Zions Bancorporation N.A. acquired a new position in shares of Bruker during the 1st quarter worth $26,000. Wipfli Financial Advisors LLC acquired a new position in shares of Bruker during the 3rd quarter worth $25,000. Ronald Blue Trust Inc. acquired a new position in shares of Bruker during the 2nd quarter worth $31,000. Householder Group Estate & Retirement Specialist LLC bought a new stake in Bruker during the 3rd quarter worth $32,000. Finally, CoreCap Advisors LLC bought a new stake in Bruker during the 2nd quarter worth $52,000. Institutional investors and hedge funds own 70.40% of the company’s stock.

Insider Activity

In other news, Director Cynthia M. Friend sold 921 shares of the business’s stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $68.26, for a total value of $62,867.46. Following the transaction, the director now directly owns 11,576 shares of the company’s stock, valued at approximately $790,177.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 27.60% of the stock is owned by company insiders.

Bruker Trading Down 2.1 %

NASDAQ BRKR opened at $72.10 on Friday. The business’s 50-day moving average price is $71.23 and its two-hundred day moving average price is $64.51. Bruker Co. has a 12 month low of $48.42 and a 12 month high of $76.81. The firm has a market capitalization of $10.58 billion, a PE ratio of 36.23, a price-to-earnings-growth ratio of 1.30 and a beta of 1.14. The company has a current ratio of 2.31, a quick ratio of 1.44 and a debt-to-equity ratio of 1.07.

Bruker (NASDAQ:BRKR – Get Rating) last released its quarterly earnings results on Thursday, February 9th. The medical research company reported $0.74 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.02. The firm had revenue of $708.40 million for the quarter, compared to analyst estimates of $697.68 million. Bruker had a return on equity of 34.13% and a net margin of 11.72%. The business’s revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.59 EPS. On average, analysts expect that Bruker Co. will post 2.55 EPS for the current year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 17th. Stockholders of record on Wednesday, March 1st will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date of this dividend is Tuesday, February 28th. Bruker’s dividend payout ratio is 10.05%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on BRKR shares. Citigroup boosted their price objective on Bruker from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, February 10th. Cowen reduced their price objective on Bruker to $75.00 in a research report on Wednesday, November 16th. One investment analyst has rated the stock with a sell rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $73.75.

Bruker Company Profile

(Get Rating)

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) Life Science, BSI Nano, and Bruker Energy and Supercon Technologies (BEST).